ChargePoint Technology launches single-use technology as part of powder transfer solutions portfolio
Company's hybrid solution claims superior performance compared with tradition single-use technologies.
Contained and sterile transfer solutions expert, ChargePoint Technology has announced new, single-use additions to its portfolio - the ChargePoint Single Use Passive (SUP) and ChargeBag PE-S with new HiPure ULP7 PE film.
Together, the two products form a high performance, single-use package for the contained and sterile transfer of pharmaceutical powders between manufacturing process steps or even facilities.
The ChargePoint SUP is a disposable version of the passive mating half of the ChargePoint SBV (Split Butterfly Valve) technology, which forms a complete hybrid system to ensure users can take advantage of the benefits of disposable technology without compromising performance. This also ensures the new single-use products are compatible with existing ChargePoint SBV systems in the field.
Constructed completely of FDA and USP Class VI compliant materials, the SUP is both lightweight and cost effective, delivering containment and sterility assurance performance while eliminating the time and cost associated with cleaning, maintenance and validation.
The new ChargeBag PE-S is a flexible, single-use product container for the handling, storage and transfer of bio-pharmaceutical powders.
Manufactured from HiPure ULP7, a new proprietary film, developed exclusively by ChargePoint Technology, and compliance tested to meet the demands of even the most critical aseptic processing environments, the solution enables extremely high levels of integrity with optimised purity and robustness characteristics.
Chris Eccles, CEO, ChargePoint Technology says: “As pharmaceutical manufacturing environments evolve, we will continue to push the boundaries of innovation and remain at the forefront of contained transfer advancements, responding to the challenges of today and tomorrow. We are excited to take our first steps into the realm of single-use technology as we look for new ways to deliver compliant, flexible solutions to our customers.”
He continues: “Although traditional single-use technologies claim to deliver the same level of performance as some of the more robust solutions, the reality is this is not the case over repeated operations. ChargePoint’s hybrid solution delivers repeatable performance as well as offering several advantages to pharmaceutical manufacturers. The convenience and control benefits associated with pre-validated, ready to use solutions, that are easily integrated and perform to the highest level of containment and sterility assurance, are invaluable for our customers”.
In line with the next generation of transfer solutions, ChargePoint Technology is also introducing its latest update of the ChargePoint SBV system, Series 3. Featuring a new and improved locking mechanism with intuitive mechanical interlocks the system is operator friendly and reduces risk of part wear. On automatic versions, quick release actuators and sensor sockets ensure fast set up and changeover while improved access to the main disc seal makes maintenance steps more convenient than ever before.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...